REMINDER: Keryx Biopharmaceuticals CEO to Provide KRX-101 Update  
         Today at the Rodman & Renshaw Techvest Healthcare Conference 
 
    NEW YORK, Oct. 21 -- Keryx Biopharmaceuticals, Inc. 
(Nasdaq: KERX; London AIM: KRX), a biopharmaceutical company focused on the 
acquisition, development and commercialization of novel pharmaceutical 
products for the treatment of life-threatening diseases, including diabetes 
and cancer, wishes to remind all interested parties that Michael S. Weiss, 
Chairman and Chief Executive Officer, will present an overview of the Company, 
including an update of its newly initiated Phase II/III clinical program for 
its lead drug candidate, KRX-101, at the Rodman & Renshaw Techvest Healthcare 
Conference in Boston. Mr. Weiss's presentation will take place today, Tuesday, 
October 21, 2003, at 12:40 p.m. EDT, in Salons J-L of the Boston Marriott Long 
Wharf Hotel. A live audio webcast will be available during the presentation at 
http://www.wallstreetwebcasting.com/webcast/rrshq/kerx / and will be archived 
for a period of 60 days.  
 
    About Keryx Biopharmaceuticals, Inc.  
    Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX; London AIM: KRX) is a 
biopharmaceutical company focused on the acquisition, development and 
commercialization of novel pharmaceutical products for the treatment of life-
threatening diseases, including diabetes and cancer. Keryx is developing KRX-
101 (sulodexide), a novel first-in-class oral heparinoid compound, for the 
treatment of diabetic nephropathy, for which Keryx is currently planning its 
U.S.-based Phase II/III clinical program. Keryx also has an active in-
licensing program designed to identify and acquire clinical-stage drug 
candidates. Additionally, Keryx is seeking partners for its KinAce(TM) drug 
discovery technology and related products. Keryx Biopharmaceuticals is 
headquartered in New York City.  
 
     KERYX CONTACT:  
     Ron Bentsur               
     Vice President - Finance & Investor Relations      
     Keryx Biopharmaceuticals, Inc.           
     Tel: 212.531.5965         
     E-mail: ron@keryx.com     
 
SOURCE  Keryx Biopharmaceuticals, Inc. 
    -0-                             10/21/2003 
    /CONTACT:  Ron Bentsur, Vice President - Finance & Investor Relations, 
Keryx Biopharmaceuticals, Inc., +1-212-531-5965 or ron@keryx.com/ 
    /Web site:  http://www.wallstreetwebcasting.com/webcast/rrshq/kerx / 
    (KERX) 
 




END